<DOC>
	<DOCNO>NCT01951053</DOCNO>
	<brief_summary>The purpose study evaluate effect JNJ-40411813 rapid eye movement sleep deep sleep ; safety , tolerability pharmacokinetics ( body study medication ) JNJ-40411813 .</brief_summary>
	<brief_title>A Study Evaluate Safety , Tolerability , Pharmacodynamics , Pharmacokinetics JNJ-404118413 Healthy Male Patients</brief_title>
	<detailed_description>This double-blind ( neither physician participant know treatment participant receives ) , placebo-controlled ( effect study medication compare effect placebo [ inactive substance ] ) , comparator-controlled ( effect study medication compare effect FDA approve market active substance [ citalopram ] ) , 3-way crossover ( method use switch participant one treatment arm another treatment arm ) study . This study double-blinded treatment placebo JNJ-40411813 ; however , open label ( people know identity intervention ) treatment citalopram . This study consist screen phase ( within 28 day prior start study medication ) , treatment phase , follow-up phase ( approximately 14 day last administration study medication ) . Participants randomly assign 1 6 sequence ( Sequences 1 , 2 , 3 , 4 , 5 , 6 ) receive JNJ-40411813 , citalopram , placebo . Each sequence consist 3 treatment period ( Period 1 , Period 2 , Period 3 ) subsequent treatment period separate wash period ( treatment ) least 7 day . Approximately , 18 participant enrol study ( 3 participant sequence ) . Safety evaluate assessment adverse event , clinical laboratory test , electrocardiogram , vital sign , physical examination evaluate throughout study duration . The total duration study participation participant approximately 10 Weeks .</detailed_description>
	<mesh_term>Citalopram</mesh_term>
	<mesh_term>Dexetimide</mesh_term>
	<criteria>Body mass index ( BMI ) 18 29.9 kg/m2 ( BMI calculate weight [ kilogram ] divide square height [ meter ] ) Significant history current significant medical illness include ( limited ) liver renal insufficiency ; significant cardiac , vascular , pulmonary , gastrointestinal , endocrine , neurologic , hematologic , rheumatologic , psychiatric , metabolic disturbance illness investigator considers clinically significant History relevant sleep disorder / receive treatment sleep disorder Regular periodic use benzodiazepine Serology positive hepatitis B surface antigen , hepatitis C antibodies HIV antibody screen Positive urine screen drug abuse positive alcohol breath test screen administration study medication Use prescription medication overthecounter medication ( include paracetamol ) , herbal medication within 2 week start study medication</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>September 2013</verification_date>
	<keyword>Healthy</keyword>
	<keyword>Safety</keyword>
	<keyword>Tolerability</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Pharmacodynamics</keyword>
	<keyword>JNJ-40411813</keyword>
	<keyword>Positive allosteric modulator</keyword>
</DOC>